



Article

Evaluation of Polymeric Matrix Loaded with Melatonin for Wound Dressing

Beata Kaczmarek-Szczepańska ¹, Justyna Ostrowska ¹, Justyna Kozłowska ¹, Zofia Szota ²,
Anna A. Brożyna ², Rita Dreier ³, Russel J. Reiter ⁴, Andrzej T. Slominski ^{5,6}, Kerstin Steinbrink ⁷
and Konrad Kleszczyński ^{7,*}

- ¹ Department of Biomaterials and Cosmetics Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, Gagarin 7, 87-100 Toruń, Poland; beata.kaczmarek@umk.pl (B.K.-S.); 285488@stud.umk.pl (J.O.); justynak@umk.pl (J.K.)
 - ² Department of Human Biology, Institute of Biology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1, 87-100 Toruń, Poland; zofia.szota@doktorant.umk.pl (Z.S.); anna.brozyna@umk.pl (A.A.B.)
 - ³ Institute of Physiological Chemistry and Pathobiochemistry, Waldeyerstraße 15, 48149 Münster, Germany; dreier@uni-muenster.de
 - ⁴ Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, TX 78229, USA; reiter@uthscsa.edu
 - ⁵ Comprehensive Cancer Center, Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; aslominski@uabmc.edu
 - ⁶ Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL 35294, USA
 - ⁷ Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, Germany; kerstin.steinbrink@ukmuenster.de
- * Correspondence: konrad.kleszczyński@ukmuenster.de; Tel.: +49-251-83-56523; Fax: +49-251-83-58646



Citation:

Kaczmarek-Szczepańska, B.; Ostrowska, J.; Kozłowska, J.; Szota, Z.; Brożyna, A.A.; Dreier, R.; Reiter, R.J.; Slominski, A.T.; Steinbrink, K.; Kleszczyński, K. Evaluation of Polymeric Matrix Loaded with Melatonin for Wound Dressing. *Int. J. Mol. Sci.* **2021**, *22*, 5658. <https://doi.org/10.3390/ijms22115658>

Academic Editor: Gianfranco Alpini

Received: 29 April 2021

Accepted: 25 May 2021

Published: 26 May 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The development of scaffolds mimicking the extracellular matrix containing bioactive substances has great potential in tissue engineering and wound healing applications. This study investigates melatonin—a methoxyindole present in almost all biological systems. Melatonin is a bioregulator in terms of its potential clinical importance for future therapies of cutaneous diseases. Mammalian skin is not only a prominent melatonin target, but also produces and rapidly metabolizes the multifunctional methoxyindole to biologically active metabolites. In our methodology, chitosan/collagen (CTS/Coll)-contained biomaterials are blended with melatonin at different doses to fabricate biomimetic hybrid scaffolds. We use rat tail tendon- and *Salmo salar* fish skin-derived collagens to assess biophysical and cellular properties by (i) Fourier transform infrared spectroscopy—attenuated total reflectance (FTIR-ATR), (ii) thermogravimetric analysis (TG), (iii) scanning electron microscope (SEM), and (iv) proliferation ratio of cutaneous cells in vitro. Our results indicate that melatonin itself does not negatively affect biophysical properties of melatonin-immobilized hybrid scaffolds, but it induces a pronounced elevation of cell viability within human epidermal keratinocytes (NHEK), dermal fibroblasts (NHDF), and reference melanoma cells. These results demonstrate that this indoleamine accelerates re-epithelialization. This delivery is a promising technique for additional explorations in future dermatotherapy and protective skin medicine.

Keywords: melatonin; scaffolds; biopolymers; collagen; chitosan; cutaneous cells; wound healing

1. Introduction

The skin is a barrier organ that separates the body from the environment, protecting against microbial, physical, and chemical insults. In addition, primary skin disease and systemic disorders with associated cutaneous symptoms can result in pathological skin lesions, such as erosions, ulcers, and chronic wounds. Although its treatment includes the removal of mechanical influences and bandages with appropriate anti-inflammatory and antibacterial agents, amputation of the limb is still very often inevitable. Melatonin

(*N*-acetyl-5-methoxytryptamine) is a ubiquitous physiological mediator that exists throughout the evolutionary scale of animals, plants, and unicellular organisms [1–5]. In mammals, it is most often characterized as a natural neurohormone synthesized in the pineal gland, from which it is released to modulate circadian rhythms [4]. In addition, many other tissues, and cells, including bone marrow [6], lymphocytes [7], retina [8], astrocytes [9], thymus [10], skin [11–13], and female reproductive organs (granulosa cells, cumulus cells, and oocytes) [14], synthesize melatonin. There is also evidence that melatonin is present in follicular fluid [15], and it is synthesized by oocytes [16,17]. Physiologically, melatonin functions as a multifaceted endogenous free radical scavenger and as a broad-spectrum antioxidant, and due to its amphiphilic nature, it can easily reach all cellular compartments [18–20]. Indeed, melatonin is ubiquitously localized in the cytosolic, membranous, mitochondrial, and nuclear compartments of the cell [21,22]. The highest melatonin concentrations are found in mitochondria [23,24], raising the possibility of functional significance for the involvement in mitochondrial activities [25,26]. For instance, most apoptotic signals originate in the mitochondria, and melatonin has well-known anti-apoptotic [27–29], anti-inflammatory [30], pro-differentiation [31–33], and oncostatic effects [21–36]. Melatonin acts through two major pathways: A receptor-mediated pathway (membrane, cytosolic, and nuclear receptors) and a receptor-independent pathway [37–39]. The receptor-mediated pathway is characterized by activating two types of membrane-specific receptors: the ML1 receptors, including MT1 (or Mel1a) and MT2 (or Mel1b) receptors, and the ML2 receptors, also called MT3 receptors. MT1 and MT2 are high-affinity receptors for melatonin with 60% homology, and their activation leads to an inhibition of the adenylate cyclase in target cells [37]. These G-protein-coupled receptors have mainly a role in the regulation of vigilance states, sleep/wake rhythms, and bone mass regulation [40,41]. Besides, acting through its receptors MT1 and MT2, melatonin activates multiple signaling pathways to modulate the activities and levels of several pivotal proteins in terms of scavenging free radicals. Melatonin, because of its electron transferability, is also engaged in complex repairing systems of damaged biomolecules. Namely, it effectively protects neurons and glial cells from A β -induced neurotoxicity and oxidative stress [38,42,43]. Thus, melatonin administration could reduce A β accumulation and enhance cognitive function against neurodegenerative progression. In other words, emerging findings are revealing that the decreased melatonin production in aged persons is considered an important factor for developing Alzheimer's disease (AD) [38,44,45]. The above features prompted us to examine the application of melatonin administered using chitosan/collagen scaffolds to discover its "undiscovered" potential with regard to wound healing.

Skin wounds are induced by thermal or electrical factors, but also by chemicals and UV radiation. The most common burns are those triggered by thermal pulses, which result in tissue damage and inflammation at the wound site. Further consequences of burns occur at the cellular stage, where reactive oxygen species (ROS) and reactive nitrogen species (RNS) are massively formed. Classic wound treatment methods based on 1% silver sulfadiazine are not sufficient because they exhibit cytotoxic activity and delay the wound healing process. The use of nanogel dressings with high water content, in combination with bioactive melatonin molecules, accelerates the healing and regeneration process of the skin. Enrichment of the composite with natural polysaccharides, such as chitosan and hyaluronic acid, guarantees the ability to absorb liquids, maintains a moist environment, and enables gas exchange. Nevertheless, the biomedical properties that favor biocompatibility and biodegradability of the described composites are also beneficial.

Hydrogels based on hyaluronic acid, chitosan, and melatonin have been in part characterized, and they have excellent physicochemical and antimicrobial properties, which support the wound healing processes and ensure biocompatibility with the skin [46]. For example, Chen et al. [47] tested the injectable melatonin-loaded carboxymethyl chitosan (CMCS)-based hydrogel, and they assumed that it induces granulation tissue formation and accelerates wound healing. Qian et al. [48] fabricated a 3D melatonin/polycaprolactone nerve guide conduit. These materials freely exchange nutrients and support long-term

structural stability. Thereby, melatonin/polycaprolactone materials may find application in nerve tissue engineering. Xu et al. [49] reported that melatonin is a bioactive substance that can effectively promote muscle recovery by inhibiting oxidative stress and inflammation. Also, 3D-printed β -tricalcium phosphate (β -TCP) scaffolds blended with melatonin were studied for bone regeneration [50]. Bone mesenchymal stem cells have shown great viability and proliferation in this type of scaffold. Manjunath et al. [51] synthesized melatonin-loaded albumin nanoparticles and entrapped them into a polycaprolactone scaffold. Such modification increased the therapeutic potential of the scaffolds for cartilage regeneration. Herein, our studies characterized scaffolds based on natural polymers loaded with melatonin as an active substance for tissue regeneration processes.

2. Results

2.1. Fourier Transform Infrared Spectroscopy—Attenuated Total Reflectance (FTIR–ATR)

FTIR-ATR spectroscopy is a fast, nondestructive, noninvasive, label-, and reagent-free, inexpensive, sensitive, and highly reproducible physicochemical tool for the characterization of polymers. Firstly, we focused on the assessment of the presence of functional groups within melatonin-enriched chitosan (CTS)/collagen (Coll). Thus, applied FTIR-ATR analysis of subjected materials sourced from fish or rats showed spectra peaks indicating their characteristic bands, i.e., I, II, and III (Figures 1 and 2). Fish-derived collagen revealed peaks at 1645 (Band I), 1554 (Band II), and 1263 cm^{-1} (Band III). In agreement with a previous study [52], strong peaks within the range of 3665–2328 cm^{-1} referred to $-\text{NH}$, $-\text{OH}$, or Amide A from collagen, were observed. A similar pattern was noticed within rat-derived collagen presented in Figure 2. It should still be stated that Amide bands themselves are sensitive to the secondary structure of the protein; however, the Amide I-III region is similar for both types of collagen. Thereby, we assume that changes in Amide A shape are triggered by the preparation method instead of changes in collagen secondary structure. Both types of collagen, either fish or rat, did not present any differences in FTIR-ATR spectra for materials containing melatonin or without this indoleamine.




Figure 1. The FTIR-ATR spectra of scaffolds based on chitosan (CTS)/collagen (Coll) (derived from *Salmo salar* fish skin) mixture with and without melatonin in a dose-dependent manner.

2.2. Scanning Electron Microscope (SEM)

SEM enables a clear observation of structures. For scaffolds, the shape and connectivity of pores may be detected. Collected results are in line with scanning electron microscopy. In these analyses, it was visible that the liophilization process allowed to obtain 3D porous structures with open interconnected pores (Figure 3). Thus, this phenomenon is crucial for designed materials as it allows for gas exchange via the dressing material, increasing the effectiveness of wound healing [53].




Figure 2. The FTIR-ATR spectra of scaffolds based on chitosan (CTS)/collagen (Coll) (derived from rat tail tendon) mixture with and without melatonin in a dose-dependent manner.




Figure 3. Scanning electron microscopy (SEM) images of CTS/Coll (fish) (A–D): (A) Without melatonin, (B) +0.001 g melatonin, (C) +0.01 g melatonin, (D) +0.1 g melatonin; and CTS/Coll (rat) (E–H): (E) Without melatonin, (F) +0.001 g melatonin, (G) +0.01 g melatonin, (H) +0.1 g melatonin.

2.3. Thermogravimetric Analysis (TG)

Thermogravimetric analysis (TGA) is an analytical technique used to determine a material's thermal stability and its fraction of volatile components by monitoring the weight change that occurs as a sample is heated at a constant rate. The next step was the assessment of water loss by resultant materials (Table 1) using gradual thermogravimetric assay where the first (T_1) and the second (T_2) stage indicate the loss of structural bound water, while the third one (T_3) refers to the degradation of the polymeric chain [54].

Table 1. Parameters of thermal decomposition of scaffolds assessed along with the maximum temperature for obtained peaks based on TG-DTG spectra.

Specimen	T_1 [°C]	T_2 [°C]	T_3 [°C]
CTS/Coll (fish)	61.23	190.43	287.51
+0.001 g melatonin	53.64	188.70	286.27
+0.01 g melatonin	58.42	175.31	289.51
+0.1 g melatonin	57.73	n.o.	289.57
CTS/Coll (rat)	60.19	175.54	292.28
+0.001 g melatonin	52.03	169.96	293.92
+0.01 g melatonin	58.08	171.76	291.45
+0.1 g melatonin	n.o.	n.o.	280.83

n.o.: peak not observed.

Obtained results revealed that temperature within T_1 and T_2 for CTS/Coll (fish) are higher than blends composed from CTS/Coll (rat). Nevertheless, T_3 inverted this trend towards rat-derived collagen, reaching 292.28 °C compared to CTS/Coll (fish) with 287.51 °C indicating different denaturation temperatures of collagens from different sources is in line with a previous report by Prus and Kozłowska [55]. Importantly, the addition of melatonin itself to the subjected scaffolds containing either fish- or rat-derived collagen did not affect their biophysical properties.

2.4. Cellular Assessments Using Cutaneous Models

Herein, we wanted to assess the difference in cell growth on subjected melatonin-enriched scaffolds, which could mimic re-epithelialization. Thus, evaluated viability of cutaneous cells with resultant IC_{50} values are presented in Figure 4, where human epidermal keratinocytes or dermal fibroblasts were tested in comparison to two human melanoma models, i.e., amelanotic (G-361) and melanotic (MNT-1) melanoma cell lines. Statistically significant enhancement was observed in cell proliferation, both, using fish or rat collagen. Namely, CTS/Coll (fish) containing melatonin triggered cell viability by 33% (0.001 g melatonin) or 26% (0.01 g melatonin) for G-361 cells, and a similar pattern of regulation was noticed for MNT-1 melanoma by 10% or 31%, respectively. Comparatively, CTS/Coll (rat) enriched by subjected melatonin enhanced cell proliferation ranging from 16% to 42% for melanoma cells and from 21% to 38% for keratinocytes/fibroblasts for scaffolds with 0.001 g melatonin. The addition of 0.01 g melatonin enhanced up to 35% and 17% for melanoma cells and human keratinocytes or fibroblasts, respectively. Interestingly, the highest dose of melatonin, i.e., 0.1 g led to a significant decrease of cell proliferation reaching its level versus the control sample ranging from 12% to 30% and from 4% to 47% for CTS/Coll (fish) and CTS/Coll (rat), respectively.




Figure 4. Human epidermal keratinocytes (NHEK), dermal fibroblasts (NHDF), as well as human amelanotic (G-361) and melanotic (MNT-1) melanoma cells, were seeded on CTS/Coll fish- or rat-derived scaffolds containing melatonin in a dose-dependent manner, cultured for 96 h, and viability was assessed using the MTT viability assay as described in Materials and Methods. Data are presented as mean +S.E.M. ($n = 6$), expressed as a percentage of the control cells (scaffold without melatonin), and IC₅₀ values were determined accordingly. Statistically significant differences versus the control were indicated as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

3. Discussion

Collagen a protein that has found wide-spread applications in medicine, due to its biocompatible and safety. It is obtained mainly from fungi, fish skin, scales, but also from the rat tail, pig or beef tissues, sea sponges, jellyfish, and egg capsules of the dogfish. Collagen isolated from different sources differs in terms of denaturation temperatures, e.g., approximately 33 °C and 39 °C for fish and rat collagen, respectively [56].

To date, the main disadvantage of collagen-based materials is their low stability in aqueous conditions. Thus, it dissolves quickly to limit its application in tissue regeneration purposes. Furthermore, it is necessary to mix collagen with other polymers and/or use so-called cross-linkers that react with collagen functional groups and improve collagen stability per se.

One of the methods to improve its biophysical properties is preparing collagen-based materials by mixing them with other macromolecules. Namely, collagen can be blended with other proteins, such as silk fibroin or elastin [57,58], but also with polysaccharides, including hyaluronic acid [59], chitosan [60], or sodium alginate [61]. Following an earlier study of Kaczmarek et al. [62], herein, we investigated different scaffolds based on collagen derived from rat tail tendon or from *Salmo salar* fish skin mixed with chitosan. Resultant matrices were assessed as carriers for melatonin. FTIR analysis was carried out to determine changes in the polymeric structure of collagen from those two different sources, as well as the impact of melatonin itself on its characteristics. The obtained FTIR spectra did not show any significant changes in the peaks' profiles. Furthermore, characteristic peaks for collagen (Amide I, II, and III), as well as a typical peak corresponding to Amide A, hydroxyl, and amine groups, were observed. This is in line with our previous study, where we confirmed that the interaction between collagen and chitosan hydrogen occurs without new covalent formation [62]; the addition of melatonin did not influence its polymeric structure. It should, however, be noted that an increased number of hydroxyl groups in the resulting biomaterials determines elevated water binding. It is highly desirable that the moisture environment is constantly maintained, avoiding skin dehydration and scar formation during wound healing, as previously shown [63,64].

3D materials with highly porous structures are desired candidates for tissue regeneration where significant enhancement of the nutrient maintenance for targeted cutaneous cells is required. We also noticed that the resultant materials kept their shapes and homogeneity despite the addition of melatonin. Finally, the presence of indoleamine did not affect the thermal stability of the resultant scaffolds what is consistent with Andonegi et al. [65], where three decomposition stages of collagen/chitosan materials were assessed. Also, our observations are in line with the previous report of Correa et al. [66], in which melatonin exerted a positive impact on wound dressing by increased water entrapment, thereby substantially improving wound healing. The authors observed that the three-layered nanofiber wound dressing containing melatonin shows remarkable wound repair capacities by reducing the wound healing duration. Moreover, the authors carried out a histopathological evaluation in which showed the complete regeneration of the epithelial layer, remodeling of wounds, collagen synthesis, and reduction in inflammatory cells.

Comparative assessment using skin cells revealed that melatonin induced prominent differences in cell viability in a dose-dependent manner, with its highest concentration negatively affecting cell proliferation. It should be here added that our previous reports revealed that melatonin as well its metabolites are present within cutaneous cells, human epidermis, but also in human melanoma cell lines [12,31,36,67,68]. Nevertheless, lower doses of this indoleamine significantly enhanced this parameter, both, for human epidermal keratinocytes and dermal fibroblasts, but also for human melanoma cells used as reference cellular models. Elevated biophysical capacities of resultant scaffolds, as well as increased numbers of proliferating cells are in line with previous reports [69,70], in which melatonin did not impact cell viability, showed good stability characteristics, and could be safely applied, thereby improving wound healing potential.

4. Materials and Methods

4.1. Reagents

Chitosan (CTS; DD = 77%, $M_v = 5.4 \times 10^5$ g/mol), Minimum Essential Medium Eagle (MEM) (1000 mg/L), 1% penicillin-streptomycin solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acetic acid, ethanol (EtOH), HEPES (1 M), HCl, isopropanol, melatonin, and non-essential amino acids (NEAA) (100×) were purchased from Sigma (St. Louis, MO, USA). Fetal bovine serum, 0.05% trypsin/0.53 mM EDTA solution, 1 × PBS (pH 7.4), L-glutamine (200 mM), AIM-V™ medium were purchased in Thermo Fisher Scientific (Waltham, MA, USA). Collagen (Coll) used in this study was sourced from *Salmon salar* fish skin [71], and isolated rat tail tendon along the procedures described previously [72,73].

4.2. Sample Preparation

Chitosan (CTS) and respective types of collagen (Coll) were dissolved in 0.1 M acetic acid, reaching the final solution of 1%. CTS/Coll was mixed in a 50/50 (*w/w*) ratio on the magnetic stirrer. Melatonin was dissolved in 3 drops of EtOH, filled by 0.1 M acetic acid to the final volume of 1 mL, and mixed together with CTS/Coll mixture. After that, the content was placed into 24-wells plates, frozen and lyophilized (ALPHA 1–2 LDplus, CHRIST, $-20\text{ }^{\circ}\text{C}$, 100 Pa, 48 h). Each scaffold (2.5 g of CTS/Coll mixture) contained melatonin in a dose-dependent manner, i.e., 0.001 g, 0.01 g, and 0.1 g. Scaffold without melatonin was used as the control sample.

4.3. Fourier Transform Infrared Spectroscopy—Attenuated Total Reflectance (FTIR–ATR)

FTIR-ATR spectra were made for each type of scaffold in the range $4000\text{--}400\text{ cm}^{-1}$ by the spectrometer (Nicolet iS110) equipped with a diamond crystal with a resolution 4 cm^{-1} . Spectra were taken with 64 scans.

4.4. Scanning Electron Microscope (SEM)

The morphology of the obtained scaffolds was studied using Scanning Electron Microscope (SEM; LEO Electron Microscopy Ltd., Cambridge, UK). SEM images have a resolution of $200\text{ }\mu\text{m}$. Samples were covered by gold to form the conductive surface for the electron beam interaction.

4.5. Thermogravimetric Analysis (TG)

Thermogravimetric analysis (TG) was performed on a TA Instruments SDT 2960 Simultaneous TGA–DTA in nitrogen and at a heating rate of $10\text{ }^{\circ}\text{C}/\text{min}$ and the heating program of $25\text{--}600\text{ }^{\circ}\text{C}$. Spectra were analyzed with the use of the TA Universal Analysis program.

4.6. Cell Culture

Normal human epidermal keratinocytes (NHEK) and normal human dermal fibroblasts (NHDF) were supplied by PromoCell (Heidelberg, Germany) and American Type Culture Collection (ATCC) (Manassas, VA, USA), respectively. NHEK were grown in Keratinocyte Growth Medium 2 supplemented with 1% penicillin-streptomycin solution. In comparison, NHDF were maintained in MEM medium supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum, 2 mM *L*-glutamine, and 1% (*v/v*) streptomycin-penicillin solution. Comparatively, a human melanoma cell model was used, such as melanotic MNT-1 cells acquired as a gift from Dr. Cédric Delevoye (Institute Curie, Paris, France) and amelanotic G-361 cell line supplied by ATCC (Manassas, VA, USA). MNT-1 cells were cultured along modified culture medium content [74], i.e., MEM medium supplemented with 20% (*v/v*) heat-inactivated fetal bovine serum, 10% (*v/v*) AIM-V™ medium, 2 mM *L*-glutamine, 10 mM HEPES, 1% (*v/v*) NEAA, and 1% (*v/v*) streptomycin-penicillin solution. G-361 cells were maintained in MEM medium supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum, 2 mM *L*-glutamine, and 1% (*v/v*) streptomycin-penicillin solution. Cells were seeded on 24-well plates at the density of 0.5×10^5 cells/well and allowed them to attach to the surface of the subjected scaffolds for 24 h. After that, cells were cultured in supplemented culture medium in a humidified atmosphere of 5% CO_2 at $37\text{ }^{\circ}\text{C}$ for 96 h, while the culture medium was exchanged every 48 h. Differences in cell viability were assessed using the MTT assay.

4.7. Cell Viability Assay

MTT assay was conducted along with the previously described procedure [75]. MTT (5 mg/mL in $1 \times \text{PBS}$) was prepared in respective culture medium (the final dilution, 1:10), 100 μL of assay reagent was added to each well, and cells were subsequently incubated for 3 h in a humidified atmosphere of 5% CO_2 at $37\text{ }^{\circ}\text{C}$. The resultant formazan crystals were dissolved using 100 μL isopropanol/0.04 N HCl, absorbance was measured at $\lambda = 595\text{ nm}$

using the BioTek ELx808™ microplate reader (BioTek Instruments, Inc., Winooski, VT, USA), results were normalized to the control cells, and IC₅₀ values were subsequently determined.

4.8. Statistical Analysis

Data were expressed as pooled means + standard error of the mean (S.E.M.) of six independent experiments ($n = 6$). Statistically significant differences between results were determined by the univariate analysis of variance (ANOVA) or the Student's *t*-Test and appropriate post-hoc analysis using GraphPad Prism 7.05 software (La Jolla, CA, USA).

All the analyses are presented as a percentage of the control sample, and a $p < 0.05$ was considered statistically significant.

5. Conclusions

This study evaluated the comparatively biophysical properties of chitosan/collagen scaffolds containing melatonin as a potential additive in polymeric matrices. Our data provides new insight into a considerable improvement of wound dressing where subjected indoleamine accelerates wound healing potential considering its application and mechanisms, as presented in Figure 5. Given that melatonin is essentially nontoxic, readily available over the counter in different formulations, and that it meets the definition of a natural product, its topical and transepidermal delivery is a promising area for full exploration in future preventive and therapeutic approaches for skin tissue engineering and wound healing.




Figure 5. The most important mechanisms of chitosan/collagen matrices loaded with melatonin and its application in wound healing.

Author Contributions: B.K.-S. designed and performed the experiments, analyzed obtained data, and wrote the first draft of the manuscript. J.O. carried out sample preparation and selected experiments while J.K. conducted collagen isolation from subjected animals. K.K. conducted the data with cutaneous cells, analyzed these results, and together with B.K.-S. obtained respective funding. Finally, K.K. and B.K.-S. evaluated all the results, made their interpretation and together with J.O., J.K., Z.S., A.A.B., R.D., R.J.R., A.T.S., K.S. drafted and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The present study was supported in some part by the grants of the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG]), grant number: KL2900/2-1 (K.K.) and Nicolauas Copernicus University in Torun, grant number: 282/2021 IDUB SD (B.K.-S.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Dziado, M.; Mierziak, J.; Korzun, U.; Preisner, M.; Szopa, J.; Kulma, A. The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders. *Int. J. Mol. Sci.* **2016**, *17*, 160. [[CrossRef](#)]
- Hardeland, R.; Fuhrberg, B. Ubiquitous melatonin—Presence and effects in unicells, plants and animals. *Trends Comp. Biochem. Physiol.* **1996**, *2*, 25–45.
- Paredes, S.D.; Korkmaz, A.; Manchester, L.C.; Tan, D.-X.; Reiter, R.J. Phytomelatonin: A review. *J. Exp. Bot.* **2009**, *60*, 57–69. [[CrossRef](#)]
- Reiter, R.J. Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions. *Endocr. Rev.* **1991**, *12*, 151–180. [[CrossRef](#)]
- Tan, D.-X.; Hardeland, R.; Manchester, L.C.; Paredes, S.D.; Korkmaz, A.; Sainz, R.M.; Mayo, J.C.; Fuentes-Broto, L.; Reiter, R.J. The changing biological roles of melatonin during evolution: From an antioxidant to signals of darkness, sexual selection and fitness. *Biol. Rev. Camb. Philos. Soc.* **2010**, *85*, 607–623. [[CrossRef](#)]
- Tan, D.-X.; Manchester, L.C.; Reiter, R.J.; Qi, W.-B.; Zhang, M.; Weintraub, S.T.; Cabrera, J.; Sainz, R.M.; Mayo, J.C. Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance. *Biochim. Biophys. Acta Gen. Subj.* **1999**, *1472*, 206–214. [[CrossRef](#)]
- Carrillo-Vico, A.; Calvo, J.R.; Abreu, P.; Lardone, P.J.; García-Mauriño, S.; Reiter, R.J.; Guerrero, J.M. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: Possible role as intracrine, autocrine, and/or paracrine substance. *FASEB J.* **2004**, *18*, 537–539. [[CrossRef](#)] [[PubMed](#)]
- Iuvone, P.M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D.C.; Chaurasia, S.S. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. *Prog. Retin. Eye Res.* **2005**, *24*, 433–456. [[CrossRef](#)] [[PubMed](#)]
- Liu, Y.-J.; Zhuang, J.; Zhu, H.-Y.; Shen, Y.-X.; Tan, Z.-L.; Zhou, J.-N. Cultured rat cortical astrocytes synthesize melatonin: Absence of a diurnal rhythm. *J. Pineal Res.* **2007**, *43*, 232–238. [[CrossRef](#)] [[PubMed](#)]
- Naranjo, M.C.; Guerrero, J.M.; Rubio, A.; Lardone, P.J.; Carrillo-Vico, A.; Carrascosa-Salmoral, M.P.; Jiménez-Jorge, S.; Arellano, M.V.; Leal-Noval, S.R.; Leal, M.; et al. Melatonin biosynthesis in the thymus of humans and rats. *Cell. Mol. Life Sci.* **2007**, *64*, 781–790. [[CrossRef](#)] [[PubMed](#)]
- Slominski, A.T.; Hardeland, R.; Zmijewski, M.A.; Slominski, R.M.; Reiter, R.J.; Paus, R. Melatonin: A Cutaneous Perspective on its Production, Metabolism, and Functions. *J. Investig. Dermatol.* **2018**, *138*, 490–499. [[CrossRef](#)] [[PubMed](#)]
- Slominski, A.T.; Pisarchik, A.; Semak, I.; Sweatman, T.; Wortsman, J.; Szczesniewski, A.; Slugocki, G.; McNulty, J.; Kausser, S.; Tobin, D.J.; et al. Serotonergic and melatonergic systems are fully expressed in human skin. *FASEB J.* **2002**, *16*, 896–898. [[CrossRef](#)] [[PubMed](#)]
- Slominski, A.; Tobin, D.J.; Zmijewski, M.A.; Wortsman, J.; Paus, R. Melatonin in the skin: Synthesis, metabolism and functions. *Trends Endocrinol. Metab.* **2008**, *19*, 17–24. [[CrossRef](#)]
- Reiter, R.J.; Tamura, H.; Tan, D.X.; Xu, X.-Y. Melatonin and the circadian system: Contributions to successful female reproduction. *Fertil. Steril.* **2014**, *102*, 321–328. [[CrossRef](#)] [[PubMed](#)]
- Shi, J.-M.; Tian, X.-Z.; Zhou, G.-B.; Wang, L.; Gao, C.; Zhu, S.-E.; Zeng, S.-M.; Tian, J.-H.; Liu, G.-S. Melatonin exists in porcine follicular fluid and improves in vitro maturation and parthenogenetic development of porcine oocytes. *J. Pineal Res.* **2009**, *47*, 318–323. [[CrossRef](#)]
- El-Raey, M.; Geshi, M.; Somfai, T.; Kaneda, M.; Hirako, M.; Abdel-Ghaffar, A.E.; Sosa, G.A.; El-Roos, M.E.A.; Nagai, T. Evidence of melatonin synthesis in the cumulus oocyte complexes and its role in enhancing oocyte maturation in vitro in cattle. *Mol. Reprod. Dev.* **2011**, *78*, 250–262. [[CrossRef](#)]
- Sakaguchi, K.; Itoh, M.T.; Takahashi, N.; Tarumi, W.; Ishizuka, B. The rat oocyte synthesizes melatonin. *Reprod. Fertil. Dev.* **2013**, *25*, 674–682. [[CrossRef](#)]
- Allegra, M.; Reiter, R.J.; Tan, D.-X.; Gentile, C.; Tesoriere, L.; Livrea, M.A. The chemistry of melatonin's interaction with reactive species. *J. Pineal Res.* **2003**, *34*, 1–10. [[CrossRef](#)]

19. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolin, I.; Herrera, F.; Martin, V.; Reiter, R.J. Regulation of antioxidant enzymes: A significant role for melatonin. *J. Pineal Res.* **2004**, *36*, 1–9. [[CrossRef](#)]
20. Tan, D.-X.; Reiter, R.J.; Manchester, L.C.; Yan, M.-T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Kohen, R.; Allegra, M.; Hardelan, R. Chemical and Physical Properties and Potential Mechanisms: Melatonin as a Broad Spectrum Antioxidant and Free Radical Scavenger. *Curr. Top. Med. Chem.* **2002**, *2*, 181–197. [[CrossRef](#)]
21. Menendez-Pelaez, A.; Reiter, R.J. Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. *J. Pineal Res.* **1993**, *15*, 59–69. [[CrossRef](#)]
22. Costa, E.J.; Shida, C.S.; Biaggi, M.H.; Ito, A.S.; Lamy-Freund, M.T. How melatonin interacts with lipid bilayers: A study by fluorescence and ESR spectroscopies. *FEBS Lett.* **1997**, *416*, 103–106. [[CrossRef](#)]
23. Martín, M.; Macías, M.; Escames, G.; León, J.; Acuña-Castroviejo, D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. *FASEB J.* **2000**, *14*, 1677–1679. [[CrossRef](#)] [[PubMed](#)]
24. Venegas, C.; García, J.A.; Escames, G.; Ortiz, F.; López, A.; Doerrier, C.; García-Corzo, L.; López, L.C.; Reiter, R.J.; Acuña-Castroviejo, D. Extrapineal melatonin: Analysis of its subcellular distribution and daily fluctuations. *J. Pineal Res.* **2012**, *52*, 217–227. [[CrossRef](#)] [[PubMed](#)]
25. Reiter, R.J.; Ma, Q.; Sharma, R. Melatonin in Mitochondria: Mitigating Clear and Present Dangers. *Physiology* **2020**, *35*, 86–95. [[CrossRef](#)] [[PubMed](#)]
26. Semak, I.; Naumova, M.; Korik, E.; Terekhov, V.; Wortsman, A.J.; Slominski, A. A Novel Metabolic Pathway of Melatonin: Oxidation by Cytochrome c. *Biochemistry.* **2005**, *44*, 9300–9307. [[CrossRef](#)] [[PubMed](#)]
27. Andrabi, S.A.; Sayeed, I.; Siemen, D.; Wolf, G.; Horn, T.F.W. Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism responsible for anti-apoptotic effects of melatonin. *FASEB J.* **2004**, *18*, 869–871. [[CrossRef](#)] [[PubMed](#)]
28. Janjetovic, Z.; Nahmias, Z.P.; Hanna, S.; Jarrett, S.G.; Kim, T.-K.; Reiter, R.J.; Slominski, A.T. Melatonin and its metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. *J. Pineal Res.* **2014**, *57*, 90–102. [[CrossRef](#)]
29. Slominski, A.T.; Zmijewski, M.A.; Semak, I.; Kim, T.-K.; Janjetovic, Z.; Slominski, R.M.; Zmijewski, J.W. Melatonin, mitochondria, and the skin. *Cell. Mol. Life Sci.* **2017**, *74*, 3913–3925. [[CrossRef](#)]
30. Kleszczyński, K.; Zillikens, D.; Fischer, T.W. Melatonin enhances mitochondrial ATP synthesis, reduces reactive oxygen species formation, and mediates translocation of the nuclear erythroid 2-related factor 2 resulting in activation of phase-2 antioxidant enzymes (γ -GCS, HO-1, NQO1) in ultraviolet radiation-treated normal human epidermal keratinocytes (NHEK). *J. Pineal Res.* **2016**, *61*, 187–197.
31. Kim, T.K.; Kleszczyński, K.; Janjetovic, Z.; Sweatman, T.; Lin, Z.; Li, W.; Reiter, R.J.; Fischer, T.W.; Slominski, A.T. Metabolism of melatonin and biological activity of intermediates of melatonergic pathway in human skin cells. *FASEB J.* **2013**, *27*, 2742–2755. [[CrossRef](#)]
32. Slominski, A.T.; Kleszczyński, K.; Semak, I.; Janjetovic, Z.; Zmijewski, M.A.; Kim, T.-K.; Slominski, R.M.; Reiter, R.J.; Fischer, T.W. Local Melatonergic System as the Protector of Skin Integrity. *Int. J. Mol. Sci.* **2014**, *15*, 17705–17732. [[CrossRef](#)]
33. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. *Mol. Cell. Endocrinol.* **2012**, *351*, 152–166. [[CrossRef](#)] [[PubMed](#)]
34. Bilska, B.; Schedel, F.; Piotrowska, A.; Stefan, J.; Zmijewski, M.; Pyza, E.; Reiter, R.J.; Steinbrink, K.; Slominski, A.T.; Tulic, M.K.; et al. Mitochondrial function is controlled by melatonin and its metabolites in vitro in human melanoma cells. *J. Pineal Res.* **2021**, *70*, e12728. [[CrossRef](#)] [[PubMed](#)]
35. Kleszczyński, K.; Bilska, B.; Stegemann, A.; Flis, D.J.; Ziolkowski, W.; Pyza, E.; Luger, T.A.; Reiter, R.J.; Böhm, M.; Slominski, A.T. Melatonin and Its Metabolites Ameliorate UVR-Induced Mitochondrial Oxidative Stress in Human MNT-1 Melanoma Cells. *Int. J. Mol. Sci.* **2018**, *19*, 3786. [[CrossRef](#)]
36. Kleszczyński, K.; Kim, T.; Bilska, B.; Sarna, M.; Mokrzynski, K.; Stegemann, A.; Pyza, E.; Reiter, R.J.; Steinbrink, K.; Böhm, M.; et al. Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells. *J. Pineal Res.* **2019**, *67*, e12610. [[CrossRef](#)] [[PubMed](#)]
37. Lalanne, S.; Fougrou-Leurent, C.; Anderson, G.M.; Schroder, C.M.; Nir, T.; Chokron, S.; Delorme, R.; Claustrat, B.; Bellissant, E.; Kermarrec, S.; et al. Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. *Int. J. Mol. Sci.* **2021**, *22*, 1490. [[CrossRef](#)]
38. Li, Y.; Zhang, J.; Wan, J.; Liu, A.; Sun, J. Melatonin regulates A β production/clearance balance and A β neurotoxicity: A potential therapeutic molecule for Alzheimer's disease. *Biomed. Pharmacother.* **2020**, *132*, 110887. [[CrossRef](#)]
39. Talib, W.H.; Alsayed, A.R.; Abuawad, A.; Daoud, S.; Mahmud, A.I. Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. *Molecules* **2021**, *26*, 2506. [[CrossRef](#)]
40. Reiter, R.J.; Tan, D.X.; Galano, A. Melatonin: Exceeding Expectations. *Physiology* **2014**, *29*, 325–333. [[CrossRef](#)]
41. Tordjman, S.; Chokron, S.; Delorme, R.; Charrier, A.; Bellissant, E.; Jaafari, N.; Fougrou, C. Melatonin: Pharmacology, Functions and Therapeutic Benefits. *Curr. Neuropharmacol.* **2017**, *15*, 434–443. [[CrossRef](#)]
42. Reiter, R.J.; Mayo, J.C.; Tan, D.-X.; Sainz, R.M.; Alatorre-Jimenez, M.; Qin, L. Melatonin as an antioxidant: Under promises but over delivers. *J. Pineal Res.* **2016**, *61*, 253–278. [[CrossRef](#)]
43. Reiter, R.J.; Paredes, S.D.; Manchester, L.C.; Tan, D.-X. Reducing oxidative/nitrosative stress: A newly-discovered genre for melatonin. *Crit. Rev. Biochem. Mol. Biol.* **2009**, *44*, 175–200. [[CrossRef](#)] [[PubMed](#)]

44. Wu, Y.-H.; Feenstra, M.G.P.; Zhou, J.-N.; Liu, R.-Y.; Toranō, J.S.; van Kan, H.J.M.; Fischer, D.F.; Ravid, R.; Swaab, D.F. Molecular Changes Underlying Reduced Pineal Melatonin Levels in Alzheimer Disease: Alterations in Preclinical and Clinical Stages. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 5898–5906. [[CrossRef](#)]
45. Wu, Y.-H.; Swaab, D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. *J. Pineal Res.* **2005**, *38*, 145–152. [[CrossRef](#)] [[PubMed](#)]
46. Soriano, J.L.; Calpena, A.C.; Rincon, M.; Perez, N.; Halbaut, L.; Rodriguez-Lagunas, M.J.; Clares, B. Melatonin nanogel promotes skin healing response in burn wounds of rats. *Nanomedicine* **2020**, *15*, 2133–2147.
47. Chen, K.; Tong, C.; Yang, J.; Cong, P.; Liu, Y.; Shi, X.; Liu, X.; Zhang, J.; Zou, R.; Xiao, K.; et al. Injectable melatonin-loaded carboxymethyl chitosan (CMCS)-based hydrogel accelerates wound healing by reducing inflammation and promoting angiogenesis and collagen deposition. *J. Mater. Sci. Technol.* **2021**, *63*, 236–245. [[CrossRef](#)]
48. Qian, Y.; Han, Q.; Zhao, X.; Song, J.; Cheng, Y.; Fang, Z.; Ouyang, Y.; Yuan, W.-E.; Fan, C. 3D melatonin nerve scaffold reduces oxidative stress and inflammation and increases autophagy in peripheral nerve regeneration. *J. Pineal Res.* **2018**, *65*, e12516. [[CrossRef](#)]
49. Xu, Y.; Chen, X.; Qian, Y.; Tang, H.; Song, J.; Qu, X.; Yue, B.; Yuan, W.E. Melatonin-Based and Biomimetic Scaffold as Muscle-ECM Implant for Guiding Myogenic Differentiation of Volumetric Muscle Loss. *Adv. Funct. Mater.* **2020**, *30*, 2002378. [[CrossRef](#)]
50. Miao, Y.; Chen, Y.; Liu, X.; Diao, J.; Zhao, N.; Shi, X.; Wang, Y. Melatonin decorated 3D-printed beta-tricalcium phosphate scaffolds promoting bone regeneration in a rat calvarial defect model. *J. Mater. Chem. B* **2019**, *7*, 3250–3259. [[CrossRef](#)]
51. Manjunath, K.S.; Subha, K.R.; Jaison, D.; Sridhar, K.; Kasthuri, N.; Gopinath, V.; Sivaperumal, P.; Shantanu, P.S. Melatonin delivery from PCL scaffold enhances glycosaminoglycans deposition in human chondrocytes—Bioactive scaffold model for cartilage regeneration. *Proc. Biochem.* **2020**, *99*, 36–47.
52. Kaczmarek, B.; Sionkowska, A.; Monteiro, F.J.; Carvalho, A.; Łukowicz, K.; Osyczka, A.M. Characterization of gelatin and chitosan scaffolds cross-linked by addition of dialdehyde starch. *Biomed. Mater.* **2017**, *13*, 015016. [[CrossRef](#)]
53. MacEwan, M.R.; MacEwan, S.; Kovacs, T.R.; Batts, J. What Makes the Optimal Wound Healing Material? A Review of Current Science and Introduction of a Synthetic Nanofabricated Wound Care Scaffold. *Cureus* **2017**, *9*, e1736. [[CrossRef](#)] [[PubMed](#)]
54. Fernandes, L.L.; Resende, C.X.; Tavares, D.S.; Soares, G.A. Cytocompatibility of chitosan and collagen-chitosan scaffolds for tissue engineering. *Polimeros* **2011**, *21*, 1–6. [[CrossRef](#)]
55. Prus, W.; Kozłowska, J. The influence of collagen from various sources on skin parameters. *Eng. Biomater.* **2018**, *21*, 14–17.
56. Kaczmarek, B.; Mazur, O. Collagen-Based Materials Modified by Phenolic Acids—A Review. *Materials* **2020**, *13*, 3641. [[CrossRef](#)]
57. Sionkowska, A.; Michalska, M.; Walczak, M. Preparation and characterization of silk fibroin/collagen sponge with nanohydroxyapatite. *Mol. Cryst. Liq. Cryst.* **2016**, *640*, 106–112. [[CrossRef](#)]
58. Vazquez-Portalatin, N.; Alfonso-Garcia, A.; Liu, J.C.; Marcu, L.; Panitch, A. Physical, Biomechanical, and Optical Characterization of Collagen and Elastin Blend Hydrogels. *Ann. Biomed. Eng.* **2020**, *48*, 2924–2935. [[CrossRef](#)] [[PubMed](#)]
59. Lou, J.; Stowers, R.; Nam, S.; Xia, Y.; Chaudhuri, O. Stress relaxing hyaluronic acid-collagen hydrogels promote cell spreading, fiber remodeling, and focal adhesion formation in 3D cell culture. *Biomaterials* **2018**, *154*, 213–222. [[CrossRef](#)]
60. Alagha, A.; Nourallah, A.; Hariri, S. Characterization of dexamethasone loaded collagen-chitosan sponge and in vitro release study. *J. Drug Deliv. Sci. Technol.* **2020**, *55*, 101449. [[CrossRef](#)]
61. Yang, X.; Lu, Z.; Wu, H.; Li, W.; Zheng, L.; Zhao, J. Collagen-alginate as bioink for three-dimensional (3D) cell printing based cartilage tissue engineering. *Mater. Sci. Eng. C* **2018**, *83*, 195–201. [[CrossRef](#)]
62. Kaczmarek, B.; Nadolna, K.; Owczarek, A.; Mazur, O.; Sionkowska, A.; Łukowicz, K.; Vishnu, J.; Manivasagam, G.; Osyczka, A.M. Properties of scaffolds based on chitosan and collagen with bioglass 45S5. *IET Nanobiotechnol.* **2020**, *14*, 830–832. [[CrossRef](#)]
63. Kaczmarek, B.; Mazur, O.; Miłek, O.; Michalska-Sionkowska, M.; Osyczka, A.M.; Kleszczyński, K. Development of tannic acid-enriched materials modified by poly(ethylene glycol) for potential applications as wound dressing. *Prog. Biomater.* **2020**, *9*, 115–123. [[CrossRef](#)] [[PubMed](#)]
64. Morgado, P.I.; Aguiar-Ricardo, A.; Correia, I.J. Asymmetric membranes as ideal wound dressings: An overview on production methods, structure, properties and performance relationship. *J. Membr. Sci.* **2015**, *490*, 139–151. [[CrossRef](#)]
65. Andonegi, M.; Heras, K.L.; Santos-Vizcaíno, E.; Igartua, M.; Hernandez, R.M.; de la Caba, K.; Guerrero, P. Structure-properties relationship of chitosan/collagen films with potential for biomedical applications. *Carbohydr. Polym.* **2020**, *237*, 116159. [[CrossRef](#)] [[PubMed](#)]
66. Correa, V.L.R.; Martins, J.A.; de Souza, T.R.; Rincon, G.D.C.N.; Miguel, M.P.; de Menezes, L.B.; Amaral, A.C. Melatonin loaded lecithin-chitosan nanoparticles improved the wound healing in diabetic rats. *Int. J. Biol. Macromol.* **2020**, *162*, 1465–1475. [[CrossRef](#)]
67. Kim, T.-K.; Lin, Z.; Li, W.; Reiter, R.J.; Slominski, A.T. N 1-Acetyl-5-Methoxykynuramine (AMK) Is Produced in the Human Epidermis and Shows Antiproliferative Effects. *Endocrinology* **2015**, *156*, 1630–1636. [[CrossRef](#)]
68. Slominski, A.; Semak, I.; Pisarchik, A.; Sweatman, T.; Szczesniowski, A.; Wortsman, J. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. *FEBS Lett.* **2002**, *511*, 102–106. [[CrossRef](#)]
69. Hafner, A.; Lovrić, J.; Voinovich, D.; Filipović-Grčić, J. Melatonin-loaded lecithin/chitosan nanoparticles: Physicochemical characterisation and permeability through Caco-2 cell monolayers. *Int. J. Pharm.* **2009**, *381*, 205–213. [[CrossRef](#)]
70. Mirmajidi, T.; Chogan, F.; Rezayan, A.H.; Sharifi, A.M. In vitro and in vivo evaluation of a nanofiber wound dressing loaded with melatonin. *Int. J. Pharm.* **2021**, *596*, 120213. [[CrossRef](#)]

71. Romić, M.D.; Sušac, A.; Lovrić, J.; Cetina-Čižmek, B.; Filipović-Grčić, J.; Hafner, A. Evaluation of stability and in vitro wound healing potential of melatonin loaded (lipid enriched) chitosan based microspheres. *Acta Pharm.* **2019**, *69*, 635–648. [[CrossRef](#)] [[PubMed](#)]
72. Kozłowska, J.; Kaczmarkiewicz, A. Collagen matrices containing poly(vinyl alcohol) microcapsules with retinyl palmitat—Structure, stability, mechanical and swelling properties. *Polym. Degrad. Stab.* **2019**, *161*, 108–113. [[CrossRef](#)]
73. Sionkowska, A.; Kozłowska, J. Properties and modification of porous 3-D collagen/hydroxyapatite composites. *Int. J. Biol. Macromol.* **2013**, *52*, 250–259. [[CrossRef](#)]
74. Chen, K.G.; Leapman, R.D.; Zhang, G.; Lai, B.; Valencia, J.C.; Cardarelli, C.O.; Vieira, W.D.; Hearing, V.J.; Gottesman, M.M. Influence of Melanosome Dynamics on Melanoma Drug Sensitivity. *J. Natl. Cancer Inst.* **2009**, *101*, 1259–1271. [[CrossRef](#)] [[PubMed](#)]
75. Carmichael, J.; DeGraff, W.G.; Gazdar, A.F.; Minna, J.D.; Mitchell, J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. *Cancer Res.* **1987**, *47*, 936–942. [[PubMed](#)]